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Abstract 
Although Coumadin® (warfarin) has been the standard out-
patient anticoagulant for long-term prevention of thrombosis 
for many decades, it presents with significant challenges for 
both patients and health care providers in optimizing stan-
dards of care including dietary and drug restrictions, regular 
monitoring of the patient's International Normalized Ratio 
(INR), and difficulty maintaining therapeutic levels. Despite 
its unmistakable effectiveness, there has been an interest 
from the medical community in developing potential alterna-
tive drug therapies. As a result, within the past three years 
the U.S. Food and Drug Administration (FDA) has approved 
the use of three new oral anticoagulant drugs ( dabigatran, 
rivaroxaban, and apixaban) specifically targeting thrombin 
or factor Xa that have overcome many of the barriers seen in 
warfarin therapy. The use of these new oral anticoagulants is 
of particular interest in patients who have failed warfarin 
therapy or for whom warfarin therapy is contraindicated, in 
situations when monitoring is not feasible or interactions are 
problematic, or if patient INR control is poor. All of these 
novel agents are currently approved for prevention of throm-
bosis in patients with nonvalvular atrial fibrillation, and with 
ongoing clinical research these agents may present health 
care providers with additional therapeutic options in a 
greater variety of disease states. For the comparative pur-
poses of this article, we have combined all of the recent clini-
cal evidence and major landmark trials for each of these new 
agents as well as benefits and drawbacks of therapy in spe-
cific patient populations when compared to warfarin. 
Introduction 
Warfarin, a vitamin K reductase antagonist (VKA), has been 
the standard outpatient anticoagulation medication for dec-
ades. Indications for use include: prophylaxis and treatment 
of embolism development, prophylaxis and treatment of 
thromboembolic complications associated with atrial fibrilla-
tion and/or cardiac valve replacement, and reduction in 
thromboembolic events such as stroke or systemic emboliza-
tion after a myocardial infarction (MI). While numerous in-
jectable forms have entered the market over the years, only 
recently have new oral agents become available.1 Warfarin 
has several drawbacks that establish a need for these new 
anticoagulants. Due to warfarin's mechanism of action inter-
fering with bio-synthesis of vitamin K dependent clotting 
factors, it takes several days to reach effective levels of anti-
coagulation. For this same reason, the effects ofwarfarin take 
days to wear off. Warfarin therapy also requires constant 
monitoring of INR to be sure the patient has the correct level 
of anticoagulation. Vitamin K is the antidote to warfarin's 
action and is present in many beverages and food products, 
creating many potentially significant dietary interactions. 
Drug-drug interactions are very common with warfarin ther-
apy as well. 
In certain patient populations there is an obvious need for 
these new anticoagulants and the goal of this article is to 
bring forth information from current research to see where 
these new medications will fall into place in regard to antico-
agulation therapy. Along with the American Heart Associa-
tion (AHA)/American Stroke Association (ASA) recommen-
dations made for a new approach to anticoagulation therapy, 
there is a greater emphasis on the pharmacist's role in drug 
recommendation to maximize the benefits of patient care 
while simultaneously minimizing the potential for adverse 
events. Therefore, continuing education, especially concern-
ing updates to current guidelines with regard to the most 
recent additions for stroke prevention, is essential in order 
for pharmacists to make decisions based not only on effec-
tive treatment strategies, but also on cost analysis and indi-
vidual patient variations. In this article, three of the new oral 
anticoagulation medications will be compared to warfarin in 
regard to efficacy, safety, cost and monitoring. 
Dabigatran (Pradaxa®) 
Dabigatran (Pradaxa®) is a direct thrombin inhibitor with an 
FDA-approved indication for the reduction in risk of stroke 
and systemic embolism in patients with nonvalvular atrial 
fibrillation. The clinical effects of dabigatran can be seen 
within a few hours, whereas warfarin takes up to two to 
three days to reach full effect. Atrial fibrillation is an in-
creasingly common arrhythmia with an incidence of greater 
than 2.3 million people in the United States and greater 
than 4.5 million people in Western Europe. It is a sign of 
underlying heart disease and poses a significant threat, pri-
marily in the form of stroke. Stroke associated with atrial 
fibrillation is generally ischemic due to clot embolization 
originating in the left atria and is 4.5 times more likely in 
this patient population.2 In the RE-LY trial, over 18,000 pa-
tients with atrial fibrillation from 967 centers and 44 coun-
tries were randomized to warfarin, dabigatran 150 mg 
twice daily, or dabigatran 110 mg twice daily.2 The primary 
endpoint of the study was reduction in stroke or systemic 
embolism, and patients were treated for an average of two 
years. Patients included in the study experienced atrial 
fibrillation and were at risk for cardiovascular or throm-
boembolic events. The average age of the study population 
was 72, mean CHADs score of 2.1, history of myocardial 
infarction (17 percent), heart failure (32 percent) and 
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including the RE-LY trial, and analyzed cost and quality-
adjusted survival.5 Results were broken up into high, me-
dium, and low risk for atrial fibrillation patients to develop a 
stroke or embolism. Dabigatran 150 mg twice daily was the 
most cost-effective in individuals that were at high risk of 
hemorrhage or stroke unless the INR was well-controlled on 
warfarin. Warfarin was cost-effective in moderate risk pa-
tients unless INR control was poor. Aspirin monotherapy 
was cost-effective for low risk patients. 
stroke (20 percent); half of the patients had no previous 
exposure to warfarin treatment. Regarding the primary 
endpoint, 198 patients in the warfarin group had a stroke 
or systemic embolism. The 150 mg dabigatran group had 
133 patients experience a stroke or systemic embolism. The 
110 mg dabigatran group had 182 patients experience 
stroke or systemic embolism. These results were analyzed 
and the conclusions were made that dabigatran 110 mg 
twice daily is noninferior to warfarin therapy (P<0.001), 
and that dabigatran 150 mg twice daily is noninferior to 
warfarin therapy (P<0.001). Compared with warfarin, ma-
jor bleeds were less for dabigatran 110 mg twice daily 
(2.74, P=0.002), but similar for 150 mg twice daily (3.22, 
P=0.32). A potential limitation to the study was that pa-
tients and investigators were not blinded to which medica-
tion was being given. They were, however, blind to the dose 
of dabigatran given. In a sub-group analysis of the RE-LY 
study, dabigatran was compared to warfarin in patients 
with atrial fibrillation who had previously experienced a 
transient ischemic attack (TIA) or stroke.3 A total of 3,623 
patients from the original RE-LY study had previously had a 
TIA or stroke and were included in the analysis. The break-
down by group was: 1,195 patients from the 110 mg dabi-
gatran twice daily group, 1,233 from the dabigatran 150 mg 
twice daily group, and 1,195 from the warfarin group. In 
these sub-groups, stroke or systemic embolism occurred in 
65 of the warfarin patients, 55 of the dabigatran 110 mg 
patients, and 51 of the dabigatran 150 mg patients. The re-
sults from this sub-group analysis were consistent with the 
original RE-LY study in that 110 mg dabigatran twice daily 
was noninferior to warfarin therapy and that 150 mg dabi-
gatran twice daily was also superior to warfarin therapy in 
preventing stroke and systemic embolism. The rates of ma-
jor bleeds were also consistent with the original RE-LY 
study. One other study showing the same results was con-
ducted using the RE-LY study's original data to compare 
two subpopulations: patients who were naive to warfarin 
or other vitamin K reductase antagonists (VKA) and pa-
tients who were VKA-experienced.4 The VKA naive group 
represented 50.4 percent of the patients in the original 
warfarin group. Stroke and systemic embolism rates were 
similar in the dabigatran 110 mg and both VKA-nai"ve and 
VKA-experienced cohorts (P=0.65; P for interaction=0.72). 
The dabigatran 150 mg group had significantly lower risk of 
stroke and embolism in both the VKA-nalve and the VKA-
experienced group (P=0.005, P=0.007, respectively; P for 
interaction=0.84). The authors of the study concluded both 
doses of dabigatran produced beneficial effects regardless 
of previous VKA exposure. Based on clinical trials, the stan-
dard 150 mg twice daily dose is superior to warfarin ther-
apy in attempt to prevent stroke and embolism in patients 
with atrial fibrillation. Also, the standard dose, 150 mg 
twice daily, of dabigatran carries a very similar risk for 
causing a bleed when compared to warfarin treatment. Only 
the 150 mg strength received FDA approval for use. 
Cost is also a major aspect of comparing medications used to 
treat the same disease state. A decision-analysis model was 
developed to compare multiple anticoagulation therapies. 
This cost-effective study utilized data from multiple trials, 
Finally, there are notable advantages and disadvantages of 
dabigatran treatment compared to warfarin. Advantages 
include a wider therapeutic window, fewer food and drug 
interactions than warfarin and frequent monitoring is not 
necessary for dabigatran use. 6 Possible disadvantages 
include the lack of an antidote for dabigatran, compliance 
issues due to twice daily dosing, more strict storage require-
ments, and dabigatran dose may need to be lowered or 
discontinued due to low renal function. Proper storage of 
dabigatran requires the patient leave the capsules in the 
original bottle, immediately close the bottle after a capsule 
was taken out, and to discard any capsules that have not 
been taken in four months. Hemodialysis is a possible option 
for the reversal of dabigatran effects but has only shown to 
remove up to 60 percent of the drug from the blood stream 
in two to three hours. Overall, dabigatran is just as effective 
as warfarin and has shown to have less severe adverse ef-
fects. It can be considered first-line anticoagulation therapy 
in atrial fibrillation patients that have adequate compliance 
and proper renal function.7 
Rivaroxaban (Xarelto®) 
Rivaroxaban (Xarelto®) is an orally active, direct competitive 
inhibitor of Factor Xa in the coagulation cascade. The major 
role of active Factor X is the generation of thrombin via pro-
teolysis of prothrombin precursors, thereby providing the 
final common link of the intrinsic and extrinsic clotting path-
ways. Factor Xa can additionally amplify the production of 
thrombin molecules through its role in the prothrombinase 
complex that consists of Factor Xa, Factor V, free calcium 
(Ca2+), and various phospholipids. Factor Xa inhibitors can 
more efficiently prevent clots than directly inactivating free 
thrombin molecules because it is calculated that one mole-
cule of Factor Xa is capable of generating approximately 138 
molecules ofthrombin.s 
Available in three different strengths: 10 mg, 15 mg and 20 
mg tablets, rivaroxaban is renally and hepatically cleared 
with high oral bioavailability. This novel anticoagulant has 
numerous benefits over traditional therapies like warfarin, 
such as lack of routine monitoring, less food and drug inter-
actions and more predictable pharmacokinetics. Since 
rivaroxaban allows for fixed doses, it has the potential to in-
crease patient adherence due to simpler medication regi-
mens. Rivaroxaban has a quick onset of action with its full 
anticoagulant effects occurring two to four hours after ad-
ministration versus warfarin's two to three days. As a result, 
rivaroxaban does not require bridging therapy pre and post-
surgery and should be discontinued at least 24 hours before 
a procedure. 
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Rivaroxaban also has a shorter terminal half-life of five to 
nine hours compared to warfarin's terminal half-life of 
approximately 40 hours.9. 10 Thus, warfarin's anticoagulant 
effects can last much longer, and overdose can lead to 
prolonged bleeding events such as intracranial or gastroin-
testinal hemorrhaging. Unlike warfarin, there is currently no 
antidote available for rivaroxaban. Consequently, in emer-
gency cases of severe bleeding or required surgery, there is 
no way to immediately reverse its effects. Since rivaroxaban 
is a relatively new drug, there is little data and limited stud-
ies available on counteracting its effects. One such study 
done in 2011 suggested the use ofprothrombin complex con-
centrate (PCC) to overcome the anticoagulation effects of 
rivaroxaban. PCC contains high amounts of blood coagulation 
factors II, VII, IX, and X and promotes the generation of 
thrombin used in clot formation. The randomized, double-
blinded, placebo-controlled crossover study performed in 12 
healthy volunteers compared rivaroxaban 20 mg twice daily 
and dabigatran lSO mg twice daily. Rivaroxaban significantly 
prolonged prothrombin time (PT) (lS.81.3 versus 12.30.7 
seconds at baseline; P<0.001), which was rapidly reversed by 
the infusion of SO units/kg of PCC on day 3 (PT=l2.81.0; 
P<0.001) versus an equal volume of saline placebo, which 
had no effect on the prolonged PT. For dabigatran there was 
no significant difference between placebo and PCC admini-
stration in neutralizing a prolonged thrombin time (TT).11 
As an alternative to warfarin, rivaroxaban was FDA approved 
in 2011 for the prevention of stroke and systemic embolism 
in patients with nonvalvular atrial fibrillation.9 The ROCKET-
AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation) was a ran-
domized, double-blinded, multinational trial that compared 
fixed-dose rivaroxaban to dose-adjusted warfarin in preven-
tion of stroke or systemic embolism. The study randomized 
14,264 patients to receive lS or 20 mg rivaroxaban daily 
with a meal or warfarin (titrated to INR 2.0-3.0). Inclusion 
criteria included moderate-to-high-risk of stroke (mean 
CHADS2 risk score=3.3) and nonvalvular atrial fibrillation. 
The primary endpoint was time to first stroke or embolism, 
which occurred in 188 patients in the rivaroxaban group (1.7 
percent) and 241 in the warfarin group (2.2 percent). Hazard 
ratio was 0.79 for the rivaroxaban group, 9S percent confi-
dence interval (CI) 0.66-0.96, and p<0.001 for noninferiority. 
The study also concluded that there was no significant differ-
ence between the rivaroxaban and warfarin groups for risk 
of major or minor bleeding events; however, the rivaroxaban 
group had lower rates of intracranial hemorrhage (0.S per-
cent versus 0.7 percent). ROCKET-AF proved that rivaroxa-
ban was safe, efficacious, and noninferior to warfarin for 
stroke and embolism prevention.12 A limitation of ROCKET 
AF was that patients on warfarin were in the therapeutic INR 
range only SS percent of the time. One study done by 
Melamed et al. defined poor anticoagulation control as time 
in therapeutic range (TTR)<60 percent, good control be-
tween 60 percent and 70 percent, and excellent anticoagula-
tion control>7S percent.14 Another study done by Morgan et 
al. found that when warfarin TTR>70 percent there were the 
greatest benefits in stroke prevention.ls Therefore, poor anti-
coagulation control with warfarin may not be a good com-
parator for all clinical situations. This inadequate warfarin 
control may not be necessarily due to poor study design, but 
instead due to complications of managing warfarin itself, 
such as diet influences and drug interactions. Even within the 
guidelines of a well-designed study, INR ratios still fall out-
side of the therapeutic range one-third of the time.16 War-
farin has been proven successful as an anticoagulant, how-
ever poor quality of anticoagulation control in clinical prac-
tice may limit its effectiveness.17 
Since there have been limited studies comparing anticoagula-
tion control of rivaroxaban versus dose-adjusted warfarin, it is 
difficult to say which offers more efficacious anticoagulation 
effects. Rivaroxaban is not considered first-line therapy for 
stroke prevention in atrial fibrillation patients and should only 
be taken into consideration as an alternative treatment choice 
for those patients contraindicated for or not well-controlled on 
warfarin. Currently, the guidelines on stroke prevention from 
the American Heart Association, American College of Cardiol-
ogy Foundation, and Heart Rhythm Society recommend dabiga-
tran as a second-line alternative to warfarin for patients with 
moderate-to-high risk of stroke. Therefore, rivaroxaban would 
be likely considered a third-line or fourth-line choice for antico-
agulation and stroke prevention.13 
Rivaroxaban is also indicated for treatment and prevention 
of deep vein thrombosis (DVT) and pulmonary embolism 
(PE). The EINSTEIN-DVT trial was a randomized, open-label, 
noninferiority study examining the safety and efficacy of ri-
varoxaban compared to traditional therapy for treatment of 
DVT. The study included 3,449 patients with acute DVT and 
without PE who were randomized to receive either rivaroxa-
ban lS mg twice daily for three weeks, followed by 20 mg 
once daily versus subcutaneous injections of enoxaparin fol-
lowed by warfarin or acenocoumarol. another VKA, for up to 
12 months. The primary outcome was recurrent venous 
thromboembolism (PE and/or DVT). The primary safety out-
come was major or clinically relevant minor bleeding. The 
primary outcome occurred in 2.1 percent of the rivaroxaban 
group and 3.0 percent of the standard-therapy group (hazard 
ratio=0.68; 9S percent CI 0.44-1.04; p<0.001). The EINSTEIN 
-DVT trial demonstrated that rivaroxaban alone was as safe 
and effective as standard therapy for treatment of acute, 
symptomatic DVT. Based on these results, rivaroxaban is 
indicated for outpatient treatment of DVT compared to stan-
dard heparin and VKA therapy.ts 
The EINSTEIN-PE trial was a randomized, open-label, nonin-
feriority trial with 4,832 patients randomized to rivaroxaban 
or enoxaparin followed by a VKA. This study was similar to 
the EINSTEIN-DVT trial except inclusion criteria were pa-
tients with PE with or without DVT. Primary outcomes and 
safety were the same. In the rivaroxaban group, the primary 
outcome of recurrent venous thromboembolism (VTE) was 
SO and 44 in the standard-therapy group (2.1 percent versus 
1.8 percent). Frequency of minor bleeding events in the ri-
varoxaban group was observed in 10.1 percent versus 11.4 
percent of the patients for the standard therapy group and 
1.1 percent to 2.2 percent for major bleeding. This study 
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demonstrated noninferiority of rivaroxaban for acute and 
long-term treatment of PE with a better side effect pro-
file.19 
Rivaroxaban is approved for DVT prophylaxis, which may 
lead to PE in patients who have undergone knee or hip sur-
gery replacement. The RECORD (Regulation of Coagulation in 
Orthopedic Surgery to Prevent Deep Venous Thrombosis and 
Pulmonary Embolism) clinical trial program included three 
studies, RECORD 1-3, for patients undergoing orthopedic 
surgery. The RECORD trials were randomized, double-
blinded studies looking at the safety and efficacy of rivaroxa-
ban compared to enoxaparin for prevention of DVT and 
accompanying PE in patients who have had hip or knee 
replacement surgery. Depending on the assigned treatment 
group, patients were also given placebo injections or placebo 
tablets. Rivaroxaban was given at least six to eight hours 
after wound closure and enoxaparin was started 12 hours 
preoperatively and restarted six to eight hours after wound 
closure. 
RECORD 1 (hip) 
• Patients randomized to receive: 
• rivaroxaban 10 mg by mouth once daily for 
31 to 39 days or 
• enoxaparin 40 mg subcutaneously once 
daily for 31 to 39 days 
• Primary endpoint: any combination of DVT, nonfatal 
PE, and all-cause mortality 30 to 42 days after surgery 
• Primary outcomes occurred in 1.1 percent of pa-
tients on rivaroxaban versus 3.7 percent of those on 
enoxaparin (absolute risk reduction 2.6 percent; 95 
percent CI 1.5-3.7; p<0.001). Major venous throm-
boembolism occurred in 0.2 percent of the rivaroxa-
ban group versus 2.0 percent of patients in the 
enoxaparin group. 
• Conclusion: Rivaroxaban was proven to be signifi-
cantly more effective than enoxaparin for thrombo-
prophylaxis in patients undergoing hip surgery.zo 
RECORD 2 (hip) 
• Patients randomized to receive: 
• rivaroxaban 10 mg by mouth once daily for 
31 to 39 days (long term) or 
• enoxaparin 40 mg subcutaneously once 
daily for 10 to 14 days (short term) 
• Primary endpoint: any combination of DVT, nonfa-
tal PE, and all-cause mortality 30 to 42 days after 
surgery 
• Analyses done in the modified intention-to-treat 
population: 864 patients randomized to the rivarox-
aban group and 869 to the enoxaparin group. 
Primary outcome of total VTE (proximal 
and/or distal VTE, nonfatal PE, and death 
from any cause) was 2.0 percent for rivarox-
aban and 9.3 percent for enoxaparin 
(absolute risk reduction 7.3 percent, 95 per-
cent CI 5.2-9.4; p<0.0001). Bleeding events 
were similar for both groups (6.6 percent 
for rivaroxaban versus 5.5 percent for 
enoxaparin; p=0.25). 
Conclusion: Extended anticoagulation (31 to 39 
days) with rivaroxaban was significantly more suc-
cessful than short term (10 to 14 days) enoxaparin 
for prevention of venous thromboembolism in pa-
tients undergoing hip surgery.21 
RECORD 3 (kneel 
• Patients randomized to receive: 
• rivaroxaban 10 mg by mouth once daily for 
10 to 14 days or 
• enoxaparin 40 mg subcutaneously once 
daily for 10 to 14 days 
• Primary endpoint: DVT, nonfatal PE, and or death 
from any cause 13 to 17 days after surgery 
• Primary outcomes observed in 79 of 824 (9.6 per-
cent) patients on rivaroxaban and 166 of 878 (18.9 
percent) patients on enoxaparin (absolute risk re-
duction 9.2 percent; 95 percent CI 5.9-12.4; 
p<0.001). 
• Conclusion: Patients undergoing knee arthroplasty 
showed 10 mg rivaroxaban was superior to 40 mg 
enoxaparin subcutaneously once daily for thrombo-
prophylaxis.22 
Currently, rivaroxaban is not recommended as a first-line 
agent for any health condition and is contraindicated in pa-
tients with poor renal function (CrC1<15 mL/min for atrial 
fibrillation and CrC1<30 mL/min for all other indications) or 
moderate to severe hepatic impairment (Child-Pugh class B 
or C).9 However, among the new novel anticoagulants, such 
as dabigatran and apixaban, rivaroxaban is the only medica-
tion FDA approved for prevention of VTE in post-orthopedic 
surgery patients. Compared to warfarin, rivaroxaban offers 
many benefits, such as lack of monitoring due to low patient 
intervariability, less food and drug interactions, and lower 
risk of intracranial hemorrhage. Rivaroxaban shows promise 
as a new anticoagulant; however, further studies and use in 
clinical practice is needed to fully understand its place 
among older and more traditional anticoagulation therapies. 
Apixaban (Eliquis®) 
Apixaban (Eliquis®), another direct Factor Xa inhibitor, pro-
vides an attractive alternative therapy for patients at high 
risk of developing clots compared to warfarin in addition to 
those who are unable or otherwise unwilling to undergo 
treatment with a VKA.23 Although only recently approved for 
use in the United States by the FDA in December of 2012, 
apixaban has shown great promise in several large, clinical 
studies that demonstrate its effectiveness as well as safety 
compared to more traditional anticoagulant therapies such 
as warfarin and aspirin. 
Apixaban is an orally active compound that is available in 2.5 
mg and 5 mg tablets with dosing up to 5 mg twice daily. Me-
tabolism of apixaban is primarily achieved through Cyto-
chromeP450 3A4 (CYP3A4) activity along with minor contri-
butions from pathways utilizing CYP1A2, CYP2C8, CYP2C9, 
and CYP2C19 in addition to being a substrate for 
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P-glycoprotein (PGP). The dose of apixaban should be re-
duced to 2.5 mg twice daily when concomitantly adminis-
tered with drugs that are strong inhibitors of CYP3A4 and 
PGP such as ketoconazole, clarithromycin, ritonavir or strong 
inducers such as carbamazepine, rifampin, or phenytoin due 
to increased risk of bleeding or stroke, respectively.24,25 Ad-
ministration of these drugs should be avoided ifthe patient is 
already receiving the reduced dose of apixaban. 
Clinical studies have shown that in patients with mild to 
moderate hepatic impairment there is no noticeable change 
in anti-Factor Xa activity. While there have been no studies to 
date detailing the effects of apixaban in patients with severe 
hepatic impairment, there is no data providing an under-
standing of how this level of damage alters its anticoagulant 
activity. Therefore, since biotransformation that renders 
apixaban inactive occurs in the liver, this drug is contraindi-
cated in patients that have severe hepatic impairment. 
Unaltered apixaban is the major component of drug concen-
trations found in the plasma and there are no active metabo-
lites. Apixaban exhibits both renal and fecal elimination with 
27 percent of the drug clearance achieved through urine and 
SO percent by gastrointestinal or biliary excretion. No dosing 
adjustments are necessary for geriatric patients or those 
with any level of renal impairment. 
At therapeutic doses, apixaban displays linear pharmacoki-
netics with a dose-dependent relationship. The oral bioavail-
ability in doses of up to 10 mg is approximately SO percent 
with maximum concentrations being achieved within three 
to four hours. Direct intravenous administrations of apixaban 
display a half-life of five hours. When taken orally, apixaban 
has prolonged absorption throughout the gastrointestinal 
tract, especially within the distal portions of the small intes-
tines and ascending colon, which contributes to an approxi-
mate half-life of twelve hours.24,2sThis characteristic allows 
for twice daily dosing in order to achieve optimal anticoagu-
lant effects in most patients. 
Currently, apixaban is only approved for reducing the risk of 
strokes or systolic emboli in patients with nonvalvular atrial 
fibrillation. The Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) 
trial that was conducted from 2006 to 2010 assessed the 
stroke risk of apixaban compared to warfarin in patients di-
agnosed with nonvalvular atrial fibrillation and at least one 
additional risk factor for stroke. As a double-blind, double-
dummy, randomized trial enrolling 18,201 patients with 
atrial fibrillation from 39 countries, ARISTOTLE randomly 
assigned patients to receive either apixaban S mg twice daily 
or warfarin with a targeted INR value of 2.5 (goal range of 2.0 
to 3.0 with 62 percent of time spent in therapeutic range) 
while comparing the primary outcome of stroke and systolic 
embolism versus the primary safety outcome of major bleed-
ing.26 Event rates for primary outcomes were defined as the 
number of patients who experienced the event divided by the 
sum of days to the first event across all patients. Safety and 
efficacy of the experimental group was evaluated through 
CHADS2 (1, 2, ~ 3), CHA2DSzVASc (1, 2, ~ 3), and HAS-BLED 
scores (0-1, 2, ~ 3), which are typically employed to deter-
mine a patient's risk score and assess the likelihood they will 
experience a major bleeding event.27 At the point of randomi-
zation, patients within each treatment group were equally 
stratified across all risk levels. 
Results of this trial displayed overall noninferiority and su-
periority of apixaban compared to warfarin in regards to 
both prevention of primary outcomes (1.27 percent versus 
1.6 percent, Cl: 0.66-0.9S, p= 0.0114) as well as the primary 
safety outcome of major bleeding (2.13 percent versus 3.09 
percent, CI: 0.6-0.8, p <0.0001).26 Additionally, fewer pa-
tients receiving apixaban discontinued treatment compared 
to those receiving warfarin across all CHADS2 scores, espe-
cially in patients with a reported CHADS2 score of three or 
higher who are considered high risk patients (p for interac-
tion= 0.02), although this was not the case with 
CHA2DS2VASc and HAS-BLED scores. 
Although the ARISTOTLE trial was very well-crafted, there 
was some discrimination in the ability of the CHADS2 score to 
accurately predict stroke risk, especially in lower risk pa-
tients, even though it is the most commonly used method for 
assessing a patient's risk level. High CHADS2 scores are di-
rectly correlated to high HAS-BLED scores and patients were 
more likely to experience major bleeding events while on 
oral anticoagulants. It is hypothesized that this association 
between bleeding risk and high scores may explain the war-
farin treatment paradox (i.e. patients at high risk of stroke 
are less likely to receive anticoagulation therapy due to a 
higher risk of bleeding). Since the results of apixaban were 
generally more beneficial than those seen with warfarin 
across all patient risk groups, the scores could possibly be 
less effective for tailoring individual patient treatment for 
those receiving apixaban. Overall, the authors postulate that 
additional studies are necessary to determine the optimal 
method of assessing bleeding risk for atrial fibrillation pa-
tients who are receiving anticoagulation therapy.26 
A previously published trial, Apixaban Versus Acetylsalicylic 
Acid to Prevent Stroke in Atrial Fibrillation Patients Who 
Have Failed or Are Unsuitable for Vitamin K Antagonist 
Treatment (AVERROES), determined the efficacy of apixaban 
versus aspirin with or without clopidogrel, which are the two 
most effective treatment options for atrial fibrillation 
patients incapable of receiving warfarin therapy. This ran-
domized, double-blind, double-dummy trial recruited S,600 
patients stratified equally to receive either apixaban S mg 
twice daily or aspirin 81 to 324 mg daily in a 1:1 ratio in or-
der to achieve 90 percent power. The trial's primary out-
comes and primary safety outcomes are identical to those of 
the ARISTOTLE trial and were conducted to finish once 226 
patients experienced a stroke or systemic emboli.28 Primary 
outcomes were monitored using a modified Haybittle-Peto 
boundary to four standard deviations (SD) once the relative 
risk (RR) crosses the critical value the first time and three 
SDs for the second time. If the RR crosses the critical value 
three times, the safety board may recommend discontinuing 
the study due to the obvious superiority of apixaban over 
aspirin. 
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Table 1. Summary table for comparison of major pharmacology points for dabigatran, rivaroxaban, & apixaban. 
Drug Dabigatran (Pradaxa®) 
Mechanism of action Direct thrombin inhibitor 
Pro drug Yes 
FDA approved dose(s) 150 mg BID 
Nonvalvular atrial FDA approved indication(s) fibrillation 
Possible reversal agents Hemodialysis* 
CrCl 15-30 mL/min-75 mg 
BID Dose adjustments Contraindicated when 
CrC1<15 mL/min 
Drug interactions PGP inhibitors or inducers, PP Is 
2012 AHA Guideline recom-
mendations 32 Class 18 
Note: Warfarin is Class IA. 
*Not a true reversal agent 
The AVERROES trial was concluded before the projected 226 
incidences of strokes/systemic emboli due to achievement of 
the above-mentioned requirements for superiority of apixa-
ban over aspirin in prevention of primary outcomes (1.6 
percent versus 3.7 percent, CI 0.32-0.62, relative risk reduc-
tion (RRR)= 57 percent). However, similar incidence of major 
bleeding was experienced between both treatment groups 
(1.4 percent versus 1.2 percent, CI 0.74-1. 75). za 
Apixaban is not considered first-line treatment for stroke 
prevention, but rather as a potential alternative to traditional 
VKA therapy once more clinical evidence for its use becomes 
available. Currently, the AHA and the ASA make no recom-
mendations toward apixaban's use over warfarin. 
Conclusion 
As of 2012, both the AHA and the ASA have updated guide-
lines to include dabigatran (Pradaxa®) and rivaroxaban 
Rivaroxaban (Xarelto®) Apixaban (Eliquis®) 
Factor Xa inhibitor Factor Xa inhibitor 
No No 
lOmgQD 
15 mg BID 5 mg BID 
20 mgQD 
Nonvalvular A-fib 
DVT prophylaxis after hip/ N onvalvular atrial knee replacement fibrillation Treatment of DVT 
Treatment of PE 
Prothrombin concentrate Prothrombin concentrate 
complex (PCC)* complex (PCC)* 
CrCl 15-50 mL/min-15 mg 
QD (atrial fibrillation) 
Contraindicated when CrCl 2.5 mg BID with 2 or more 
<15 mL/min (atrial fibrilla- of the following: 
tion) age > 80 years, 
Contraindicated when CrCl < weight <60 kg, 
30 mL/min (all indications sCr > 1.5 mg/dL 
except A-fib) 
CYP3A4 substrates, CYP3A4 substrates, 
PGP inhibitors or inducers PGP inhibitors or inducers 
Class Ila B N/A 
(Xarelto®) in treatment algorithms for primary and secon-
dary prevention of stroke with specific agent selection based 
on level of evidence, risk factors, costs, drug interaction po-
tential, clinical characteristics (e.g. INR) and personal prefer-
ence.Jo, 31 Recommendations for apixaban (Eliquis®) are in-
cluded below, although they have not been formally en-
dorsed by the AHA/ ASA guidelines. 
With the conclusion of a considerable number of landmark 
trials detailing the numerous benefits as well as drawbacks 
of three recent additions to the previously singular list of oral 
anticoagulants available on the market, health care providers 
have begun to see potential alternatives in therapeutic man-
agement for nonvalvular atrial fibrillation patients requiring 
long-term stroke prevention. As more evidence becomes 
available, these drugs may receive additional therapeutic 
indications, thereby broadening their use in contemporary 
medicine. 
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